Frequency Exchange Corp. (TSXV: FREQ | OTCQB: FRECF | FSE: YC6) announced that its flagship NIKKI™ Wellness Technology platform is the principal partner of Superhuman 2: The Rebirth, a four-part docuseries debuting globally this October. The production premiered as an Official Selection of the DaVinci International Film Festival on September 26, 2026, with a red-carpet event at the Saban Theatre in Beverly Hills scheduled for October 4, 2026, and a worldwide digital release set for October 30, 2026. The announcement coincides with an extension of the company's ongoing private placement offering, with investors watching both commercial momentum and financing milestones.

Key Points

  • Frequency Exchange Corp. (TSXV: FREQ | OTCQB: FRECF | FSE: YC6) announced the global premiere of Superhuman 2: The Rebirth featuring NIKKI™ Wellness Technology as principal partner.
  • The docuseries global digital release is scheduled for October 30, 2026, following a Beverly Hills red-carpet premiere on October 4, 2026.
  • The company's private placement offering closing date has been extended to October 31, 2026; the first tranche raised gross proceeds of $427,057 from 1,708,230 units at $0.25 per unit.
  • Investors may be watching how the docuseries exposure supports NIKKI™ commercialisation across North America, the Middle East, and other international markets.

NIKKI™ Wellness Technology Takes Centre Stage in Award-Winning Filmmaker's Docuseries

Frequency Exchange's NIKKI™ Wellness Technology, described as a frequency-based wearable wellness platform, is prominently integrated throughout Superhuman 2: The Rebirth as a leading innovator in emerging wellness technology. The four-part investigative docuseries was created by award-winning filmmaker Caroline Cory and examines emerging scientific perspectives on human potential, perception, and cognitive performance. The release states that NIKKI™ is featured within real-world observational settings, offering audiences context on frequency-based wellness programs aligned with the company's commercialisation narrative.

Docuseries Premiere Timed to Frequency Exchange's North American and International Rollout

The company describes the docuseries partnership as a meaningful visibility milestone as it advances commercialisation across North America, the Middle East, and other international markets. CEO Stephen Davis stated in the announcement that the premiere "places NIKKI at the forefront of wellness technology at a pivotal moment in our commercial rollout," adding that the exposure is expected to support global expansion efforts and strengthen market awareness. The disclosure suggests the company views the production as a strategic marketing vehicle rather than a standalone transaction.

Private Placement Extension Provides Additional Time to Finalise Second Tranche Subscriptions

Concurrent with the docuseries announcement, Frequency Exchange disclosed that the TSX Venture Exchange has approved an extension of its non-brokered private placement offering closing date to October 31, 2026. Units are priced at $0.25, with each unit comprising one common share and one-half common share purchase warrant exercisable at $0.40 for 12 months from issuance, subject to an acceleration clause. The first tranche, closed September 11, 2026, raised gross proceeds of $427,057 through the issuance of 1,708,230 units. The extension is intended to accommodate continued investor interest and allow finalisation of second-tranche subscriptions.